Detalhe da pesquisa
1.
3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial.
J Am Coll Cardiol
; 70(23): 2852-2862, 2017 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29100702
2.
Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results.
JACC Cardiovasc Interv
; 9(11): 1178-87, 2016 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27282601